![](https://d3ilqtpdwi981i.cloudfront.net/qMox65AmOwfx6gKBVaZkMLB1F_I=/0x41:371x521/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/23/0e/c2/230ec287-35f4-416f-add9-010b3f6822a5/BHSF%20Pineapple%20Logo%20%28Imported%20Works%29.png)
Article
Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.
All Publications
Publication Date
6-2-2023
Presented At:
ASCO
Content Type
Poster
Citation Information
Yolcar Chamorro, Ana Sandoval Leon, Manmeet Ahluwalia, Reshma Mahtani, et al.. "Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review." (2023) Available at: http://works.bepress.com/reshma-mahtani/113/